share_log

BTIG Initiates Coverage On Theravance Biopharma With Buy Rating, Announces Price Target of $21

BTIG Initiates Coverage On Theravance Biopharma With Buy Rating, Announces Price Target of $21

BTIG以买入评级启动对Theravance Biopharma的报道,宣布目标股价为21美元
Moomoo 24/7 ·  04/12 07:42

BTIG analyst Julian Harrison initiates coverage on Theravance Biopharma (NASDAQ:TBPH) with a Buy rating and announces Price Target of $21.

BTIG分析师朱利安·哈里森以买入评级启动了对Theravance Biopharma(纳斯达克股票代码:TBPH)的报道,并宣布目标股价为21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发